News | August 22, 2013

BioVentrix Announces First Use of Revivent System for Heart Failure Treatment in Germany

August 22, 2013 – BioVentrix announced the successful first use of its Revivent Myocardial Anchoring System via the Less Invasive Ventricular Enhancement (LIVE) procedure in Germany. The successful procedure was performed on a 54-year-old man suffering from advanced heart failure at the Schön Klinik Vogtareuth in Vogtareuth, Germany.

“As a result of a heart attack, this patient suffered from heart failure for two years that, despite intervention with [a] coronary angioplasty and medication, continued to worsen and seriously affected his quality of life,” said Prof. Ralph Haberl, professor of internal medicine and cardiology at the University of Munich, and the patient’s private cardiologist. “The patient was critically ill and had exhausted all other available treatment options.”

As part of the patient’s previous treatment, Haberl implanted an automatic implantable cardioverter-defibrillator (ICD) as a palliative treatment for ventricular tachycardia, an abnormal life-threatening heart rhythm that often results after a heart attack in which a large amount of scar tissue is created. Magnetic resonance imaging (MRI) of the heart demonstrated an ejection fraction of only 12 percent and significant damage, including scar tissue that extended to the septum and the anterior left ventricular wall. An interdisciplinary team led by Dr. Albert Schütz, chief of heart surgery at the Schön Klinik Vogtareuth, performed the LIVE procedure. 

“The Revivent System was successfully placed using the LIVE procedure, which removes the need for cardiopulmonary bypass and, unlike conventional volume-reduction surgery, does not require an incision into the heart,” said Schütz. “The entire procedure was uncomplicated, the patient was extubated the same day and he continues to do very well.”

During the post-operative evaluation, Haberl and his team noted an immediate decrease in left ventricular end system volume index (LVESVI), a predictive indicator of survival for heart failure patients, from 289 mL/m2 to 98 mL/m2, and an increase in ejection fraction to 33 percent. “The LIVE procedure should be considered as a promising treatment option in severe heart failure after myocardial infarction,” said Haberl.

During a heart attack the portion of the left ventricle (LV) deprived of blood dies, creating a scar that does not contract along with the rest of the LV, and prevents it from efficiently pumping blood to the body. As the volume-overloaded LV enlarges, heart failure (HF) develops and worsens, severely impairing quality of life. The LIVE procedure is based upon a well-defined law of physics called the law of Laplace, which describes the relationship between the radius and pressure of the LV, and its resulting wall tension. Increased wall tension is the underlying cause of LV enlargement, worsening heart failure symptoms and ultimately patient death. Reducing wall tension is key to preventing further LV enlargement and treats the progression of the disease. The Revivent System is uniquely designed to directly reduce the LV radius, which in turn decreases wall tension and interrupts the ongoing, destructive process of heart failure.

Prior to the Revivent System, reshaping of the left ventricle used an invasive procedure known as surgical ventricular restoration (SVR), which required stopping the beating heart and supporting it with cardiopulmonary bypass, while incisions into the heart muscle were made to remove the scarred, non-functioning LV tissue. The invasive nature of SVR limits the number of patients for whom the procedure may be performed due to the fragile nature of this patient population. In contrast, the LIVE procedure using the Revivent System is performed without the need of cardiopulmonary bypass or making incisions into the heart.

“We are very pleased with the adoption of the Revivent System and the LIVE procedure by the cardiac surgery team in Germany,” said Kenneth Miller, president and CEO of BioVentrix. “We believe that our technology not only secures optimal clinical outcomes and improves the quality of life for heart failure patients, but also diminishes the risk inherent in the previous gold standard of conventional SVR.”

For more information: www.bioventrix.com

Related Content

First Canadian Patient Implanted With CardioMEMS Heart Failure Sensor
News | Heart Failure| June 23, 2017
In a Canadian first, a medical team has implanted the wireless CardioMEMS HF device inside a heart failure patient. The...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
Mitral Valve regurgitation showed on an echocardiogram, cardiac ultrasound

Mitral valve regurgitation showed on an echocardiogram. Image from Toshiba.

News | Heart Valve Technology| June 15, 2017
June 15, 2017 — 4C Medical Technologies Inc., a developer of minimally invasive therapies for structural heart diseas
Sponsored Content | Videos | Heart Valve Technology| June 14, 2017
A discussion with Rebecca Hahn, M.D., FASE, director of interventional echocardiography and professor of medicine at

An example of porcine cartdiac stem cells. Photo from the University of Miami Miller School of Medicine.

 

News | Stem Cell Therapies| June 12, 2017
June 12, 2017 — Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that hear
FDA clears Claret Medical Sentinel embolic protection device for TAVR
Feature | Heart Valve Technology| June 09, 2017
June 5, 2017 – The U.S.
LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017
News | Heart Valve Technology| May 31, 2017
LivaNova PLC recently announced the presentation of data from multiple studies demonstrating the safety and...
BioVentrix Announces Germany's First Revivent TC TransCatheter Ventricular Enhancement Procedure
News | Heart Failure| May 31, 2017
BioVentrix Inc. recently announced the first clinical use of its closed-chest Revivent TC TransCatheter Ventricular...
Arto System Shows Promise as Less-Invasive Therapy for Heart Failure Patients
News | Heart Failure| May 26, 2017
Recent outcomes from the MAVERIC clinical trial confirm earlier positive findings that MVRx’s Arto System safely and...
Overlay Init